Continuous low-dose oral chemotherapy in recurrent and persistent carcinoma of cervix following chemoradiation: a comparative study between prolonged oral cyclophosphamide and oral Etoposide.

Autor:	Baruah U; Department of Gynaecologic Oncology, Dr. B. Borooah Cancer Institute, Guwahati, Assam, India., Barmon D; Department of Gynaecologic Oncology, Dr. B. Borooah Cancer Institute, Guwahati, Assam, India., Hazarika M; Department of Medical Oncology, Dr. B. Borooah Cancer Institute, Guwahati, Assam, India., Deka P; Department of Gynaecologic Oncology, Dr. B. Borooah Cancer Institute, Guwahati, Assam, India., Kataki AC; Department of Gynaecologic Oncology, Dr. B. Borooah Cancer Institute, Guwahati, Assam, India., Shrivastava S; Department of Gynaecologic Oncology, Dr. B. Borooah Cancer Institute, Guwahati, Assam, India.
Jazyk:	angličtina
Zdroj:	Indian journal of palliative care [Indian J Palliat Care] 2014 Sep; Vol. 20 (3), pp. 208-11.
DOI:	10.4103/0973-1075.138396
Abstrakt:	Aim: To compare the efficacy and toxicities of low-dose oral cyclophosphamide and oral etoposide in patients with persistent and recurrent cervical cancer with gross pelvic disease following full course of chemoradiation therapy. Materials and Methods: 30 patients with recurrent and persistent cervical cancer with gross pelvic disease were enrolled in this trial. The patients were randomly divided into two groups of 15 patients each with one group receiving low dose oral cyclophosphamide (100 mg/day) and the other group receiving low-dose oral etoposide (50 mg/day). Results were statistically analysed by IBM SPSS Statistics 19. Results: Oral etoposide was not well tolerated with grade 2 neutropenia occurring in 33.3% and grade 3 neutropenia in 6.6% and thrombocytopenia occurring in 13.3%. Oral cyclophosphamide group on the other hand was better tolerated with none of the patients having thrombocytopenia and 6.6% patients having grade 2 neutropenia. There were two complete response (15.38%) and one partial response at the end of study (7.6%) in the cyclophosphamide group whereas there was no complete response and two partial response (16.6%) in the oral etoposide group. Conclusion: Long-term, low-dose oral etoposide was found to be less tolerated without any significant effect with patients with persistent and recurrent cervical cancer with gross pelvic disease following full course of chemoradiation therapy in contrast to oral cyclophosphamide which was found to be effective and well-tolerated by the patients.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu